1. Indications and Usage
\nLocally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC):
\nOsimertinib is indicated for the treatment of patients with locally advanced or metastatic NSCLC whose tumors have specific sensitizing EGFR mutations (exon 19 deletions or exon 21 L858R mutations).
\nMetastatic NSCLC with EGFR T790M Mutation:
\nIndicated for the treatment of patients with metastatic NSCLC whose tumors have the T790M mutation, as detected by an FDA-approved test.
\n2. Dosage and Administration
\nRecommended Dosage:
\nDose: 80 mg orally once daily.
\nAdministration: Can be taken with or without food. If a dose is missed, it may be taken as soon as possible unless the next dose is due within 12 hours.
\nDose Modifications:
\nReduce dose to 40 mg once daily for certain adverse reactions (e.g., ILD, QTc prolongation, severe skin toxicity).
\n3. Mechanism of Action
\nEGFR TKI:
\nOsimertinib is an irreversible tyrosine kinase inhibitor of both EGFR sensitizing mutations (e.g., exon 19 del, L858R) and the T790M resistance mutation.
\nPhysiological Effect:
\nIt inhibits the phosphorylation of EGFR and downstream signaling pathways (such as PI3K\/AKT and MAPK), thereby inhibiting tumor cell proliferation and inducing apoptosis.
\n4. Safety and Warnings
\nInterstitial Lung Disease (ILD):
\nSevere, fatal, or life-threatening ILD has been reported. Permanently discontinue in patients who develop ILD.
\nQTc Interval Prolongation:
\nOsimertinib can prolong the QTc interval. Avoid use in patients with congenital long QT syndrome. Monitor ECG and electrolytes periodically.
\nEmbryo-Fetal Toxicity:
\nMay cause fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for at least 6 weeks after the final dose.
\n5. Adverse Reactions
\nMost Common:
\nDiarrhea, rash, fatigue, decreased appetite, dry skin, nail toxicity (paronychia), cough, and nausea.
\nSerious Adverse Events:
\nILD\/pneumonitis, QTc prolongation, cardiomyopathy, and keratitis.
\n6. Drug Interactions
\nStrong CYP3A4 Inducers:
\nAvoid concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John’s wort) as they may significantly decrease osimertinib exposure.
\nBCRP Substrates:
\nOsimertinib is a BCRP inhibitor. Monitor patients for potential toxicity when used with BCRP substrates (e.g., rosuvastatin).
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Osimertinib Mesylate.
\nStorage:
\nStore at room temperature (20\u00b0C to 25\u00b0C or 68\u00b0F to 77\u00b0F). Keep in original package to protect from moisture.<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u6cf0\u745e\u6c99 \u00ae(Tagrisso\u00ae)
\nGeneric Name: Osimertinib Mesylate
\nStrength: 80mg per tablet, 30 tablets per box
\nManufacturer: AstraZeneca AB
\nMarketing Authorization Holder: AstraZeneca Investment (China) Co., Ltd.
\nApproval Date in China: March 27, 2017
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20170167
\nStorage: Store below 30\u2103, sealed, protect from moisture and direct sunlight, keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Osimertinib Mesylate \uff08Tagrisso\uff09<\/p>\n","protected":false},"featured_media":3333,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[75],"product_cat":[27],"product_tag":[],"class_list":["post-3332","product","type-product","status-publish","has-post-thumbnail","product_brand-astrazeneca","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n